Aeterna Zentaris Inc. (AEZ.TO) 1.27 $AEZ.TO
Aeterna Zentaris: Poster Presentation at AACR Meeting Provides Rationale for New Therapeutic Opportunities in Oncology with Erk Inhibitors
PR Newswire - Wed Apr 09, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:AEZ) (the "Company"

today announced that a poster on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, provides rationale for new therapeutic opportunities in oncology with this compound. The poster, titled, "Erk Inhibition as a Therapeutic Option for the Treatment of Raf- and Mek- Inhibitor Resistant Tumors", I. Seipelt, P. Schmidt, H. Märzhäuser, M. Gerlach, K. Jung, T. Schuster and M. Teifel, was presented yesterday by Irene Seipelt, Ph. D., Director, Preclinical Development at Aeterna Zentaris, during a poster session at the American Association for Cancer Research Annual Meeting in San Diego, California.
Aeterna Zentaris to Present Poster on New Therapeutic Opportunities in Oncology with Erk Inhibitors at AACR Meeting in San Diego
CNW Group - Tue Apr 01, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"

today announced that a poster will be presented on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, during the American Association for Cancer Research (AACR) Annual Meeting, which will be held April 5-9, 2014 in San Diego, California.
Aeterna Zentaris Announces Effectiveness of $50 Million Shelf Registration Statement for "At-the-Market" Common Share Issuance Programs
PR Newswire - Fri Mar 28, 4:23PM CDT
All amounts are in US dollars
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2013 Financial and Operating Results
PR Newswire - Thu Mar 20, 3:30PM CDT
All amounts are in US dollars
Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2013 Financial and Operating Results on March 20, 2014
CNW Group - Wed Mar 12, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"

will announce its fourth quarter and full-year 2013 financial and operating results after market close on Thursday, March 20, 2014. The Company will host a conference call to discuss these results on Friday, March 21, 2014, at 8:30 a.m., Eastern Time.
NASA Television Airs Departure of Commercial Cargo Ship from Space Station
Close-Up Media - Thu Feb 20, 12:18AM CST
NASA announced that Orbital Sciences' Cygnus cargo spacecraft, which delivered almost a ton-and-a-half of supplies and scientific experiments to the International Space Station in January, completes its month-long mission to the orbiting laboratory Tuesday, Feb. 18.
Aeterna Zentaris: Article on Phase 2 Results for Zoptarelin Doxorubicin in Endometrial Cancer Published in the International Journal of Gynecological Cancer
PR Newswire - Tue Feb 04, 6:30AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:AEZ) (the "Company"

today announced that an article on Phase 2 results for zoptarelin doxorubicin (AEZS-108) in endometrial cancer has been published in the February issue of the International Journal of Gynecological Cancer. Zoptarelin doxorubicin, is the Company's cytotoxic peptide conjugate which specifically targets luteinizing hormone-releasing hormone ("LHRH"

receptors. The article, "Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors: A Multicenter Phase 2 Trial (AGO-GYN5)", Emons G., Gorchev G., Harter P., Wimberger P., Stähle A., Hanker L., Hilpert F., Beckmann M.W., Dall P., Gründker C., Sindermann H., Sehouli J., outlines results of this study which had been previously presented at the European Society of Gynaecological Oncology's ("ESGO"

annual meeting in September 2011. The article is currently available at this link.
Aeterna Zentaris: Presentations on Zoptarelin Doxorubicin and Disorazol Z Conjugates at Upcoming International Symposium on GnRH
PR Newswire - Mon Feb 03, 6:30AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:AEZ) (the "Company"

today announced that presentations on two of its oncology compounds, zoptarelin doxorubicin (AEZS-108) and disorazol Z, will be made during the 11th International Symposium on GnRH, in Salzburg, Austria, February 9 -11, 2014.
Aeterna Zentaris Inc concludes USD13.2m public offering
M2 - Wed Jan 15, 8:14AM CST
Canadian-based biopharmaceutical company Aeterna Zentaris Inc (NasdaqCM :AEZS) (TSX:AEZ) reported the completion of its public offering of 11.0m units for net proceeds of USD12.2m on Tuesday.
Aeterna Zentaris Announces Closing of US$13.2 Million Public Offering of Common Shares and Warrants
CNW Group - Tue Jan 14, 10:15AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"

today announced the closing of its previously announced public offering of 11.0 million units (the "Offering"

generating net proceeds of approximately US$12.2 million, with each unit consisting of one common share and 0.8 of a warrant to purchase one common share, at a purchase price of US$1.20 per unit. Each warrant is exercisable for a period of five years at an exercise price of US$1.25 per share. Canaccord Genuity Inc. acted as the sole book-running manager, and Maxim Group LLC, H. C. Wainwright & Co., LLC and MLV & Co LLC acted as co-managers for the Offering.
Aeterna Zentaris Inc prices public offering of 11.0m units
M2 - Fri Jan 10, 6:52AM CST
Biopharmaceutical company Aeterna Zentaris Inc (TSX:AEZ) revealed on Thursday that it has priced its public offering of 11.0m units at a purchase price of USD1.20 per unit.
Aeterna Zentaris Announces Pricing of US$13.2 Million Public Offering of Common Shares and Warrants
CNW Group - Thu Jan 09, 7:31AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:AEZ) (the"Company"

today announced the pricing of its previously announced public offering of 11.0 million units (the "Offering"

, with each unit consisting of one common share and 0.8 of a warrant to purchase one common share, at a purchase price of US$1.20 per unit. Each warrant will be exercisable for a period of five years following the issuance thereof at an exercise price of US$1.25 per share. Net proceeds from the Offering are expected to be approximately US$12.2 million, after deducting underwriting commissions and other expenses related to the Offering.